Are you a health professional?
This page does not replicate the other information in this handbook but provides additional details or context most relevant to professionals.
Practice guidelines for professionals
Clinicians should not offer, and should discourage use of, acetyl-l-carnitine for the prevention of CIPN in patients with cancer (type of recommendation: evidence based, harms outweigh benefits; Evidence quality: high; Strength of recommendation: strong).
Clinicians should not offer the following agents for the prevention of CIPN to patients with cancer undergoing treatment with neurotoxic agents (type of recommendation: evidence based, no benefits; Evidence quality: intermediate; Strength of recommendation: moderate):
- All-trans retinoic acid
- Calcium magnesium
- Diethyldithiocarbamate (DDTC)
- Glutathione (GSH) for patients receiving paclitaxel/carboplatin chemotherapy
- Goshajinkigan (GJG)
- Omega-3 fatty acids
- Org 2766
- Recombinant human leukemia inhibitory factor
- Vitamin B
- Vitamin E
Helpful link for professionals
Health professional comment
We invite health professionals to contribute expertise or send us questions.
"*" indicates required fields